adc therapeutics is a biotechnology company located in lausanne, vaud, switzerland.
Company profile
Ticker
ADCT
Exchange
Website
CEO
Christopher John Martin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
ADCT stock data
Latest filings (excl ownership)
424B3
Prospectus supplement
15 Mar 24
424B3
Prospectus supplement
15 Mar 24
EFFECT
Notice of effectiveness
15 Mar 24
EFFECT
Notice of effectiveness
15 Mar 24
EFFECT
Notice of effectiveness
15 Mar 24
POS AM
Prospectus update (post-effective amendment)
13 Mar 24
POS AM
Prospectus update (post-effective amendment)
13 Mar 24
POS AM
Prospectus update (post-effective amendment)
13 Mar 24
ARS
2023 FY
Annual report to shareholders
13 Mar 24
10-K
2023 FY
Annual report
13 Mar 24
Transcripts
ADCT
Earnings call transcript
2023 Q4
13 Mar 24
ADCT
Earnings call transcript
2023 Q3
7 Nov 23
ADCT
Earnings call transcript
2023 Q2
8 Aug 23
ADCT
Earnings call transcript
2023 Q1
9 May 23
ADCT
Earnings call transcript
2022 Q4
28 Feb 23
ADCT
Earnings call transcript
2022 Q3
9 Nov 22
ADCT
Earnings call transcript
2022 Q2
9 Aug 22
ADCT
Earnings call transcript
2022 Q1
9 May 22
ADCT
Earnings call transcript
2021 Q2
7 Aug 21
ADCT
Earnings call transcript
2021 Q1
9 May 21
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q3 2023
69.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 42 |
Opened positions | 3 |
Closed positions | 19 |
Increased positions | 13 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 35.41 bn |
Total shares | 57.23 mm |
Total puts | 5.40 k |
Total calls | 2.20 k |
Total put/call ratio | 2.5 |
Largest owners | Shares | Value |
---|---|---|
Redmile | 14.18 mm | $12.72 bn |
HPWH TH | 7.45 mm | $275.20 mm |
Auven Therapeutics | 6.33 mm | $12.28 mm |
Prosight Management | 5.40 mm | $4.85 bn |
AZN Astrazeneca | 4.01 mm | $0.00 |
Sio Capital Management | 3.29 mm | $2.96 bn |
Citadel Advisors | 2.90 mm | $2.60 bn |
Millennium Management | 2.65 mm | $2.38 bn |
Frazier Life Sciences Management | 1.65 mm | $1.48 bn |
BAC Bank Of America | 1.53 mm | $1.38 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Feb 24 | Redmile | Cash-settled Swaps Common Shares | Buy | Acquire P | No | No | 3.9913 | 107,590 | 429.42 k | 107,590 |
2 Feb 24 | Redmile | Cash-settled Swaps Common Shares | Buy | Acquire P | Yes | No | 3.5872 | 11,159 | 40.03 k | 11,159 |
2 Feb 24 | Redmile | Cash-settled Swaps Common Shares | Buy | Acquire P | No | No | 3.5872 | 144,517 | 518.41 k | 144,517 |
1 Feb 24 | Redmile | Cash-settled Swaps Common Shares | Buy | Acquire P | Yes | No | 3.5105 | 15,867 | 55.70 k | 15,867 |
1 Feb 24 | Redmile | Cash-settled Swaps Common Shares | Buy | Acquire P | No | No | 3.5105 | 205,483 | 721.35 k | 205,483 |
1 Feb 24 | Redmile | Cash-settled Swaps Common Shares | Other | Dispose J | Yes | No | 3.3848 | 19,700 | 66.68 k | 1,180,136 |
31 Jan 24 | Redmile | Cash-settled Swaps Common Shares | Buy | Acquire P | No | No | 3.2605 | 150,000 | 489.08 k | 150,000 |
30 Jan 24 | Redmile | Cash-settled Swaps Common Shares | Buy | Acquire P | No | No | 3.1446 | 100,000 | 314.46 k | 100,000 |
29 Jan 24 | Redmile | Cash-settled Swaps Common Shares | Buy | Acquire P | No | No | 3.0824 | 150,000 | 462.36 k | 150,000 |
26 Jan 24 | Redmile | Cash-settled Swaps Common Shares | Buy | Acquire P | No | No | 2.6571 | 100,000 | 265.71 k | 100,000 |
News
Guggenheim Initiates Coverage On ADC Therapeutics with Buy Rating, Announces Price Target of $11
28 Mar 24
RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $8 Price Target
14 Mar 24
Dollar Tree Reports Weak Earnings, Joins Tesla, Arcos Dorados And Other Big Stocks Moving Lower On Wednesday
13 Mar 24
ADC Therapeutics Q4 Adjusted EPS $(0.97) May Not Be Comparable To $(0.50) Estimate, Sales $16.79M Beat $15.33M Estimate
13 Mar 24
Earnings Scheduled For March 13, 2024
13 Mar 24
Press releases
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
13 Mar 24
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
5 Mar 24
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
27 Feb 24
ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
4 Jan 24